Trial Search Results
Hydroxychloroquine/Atorvastatin in the Treatment of Osteoarthritis (OA) of the Knee
The purpose of this study of a combination therapy of hydroxychloroquine and atorvastatin is to learn about the effects in inflammation and pain in patients with Osteoarthritis of the knee. These medications are FDA approved and commercially available.
Stanford is currently not accepting patients for this trial.
- Drug: Hydroxychloroquine/Atorvastatin
1. Ambulatory subjects with OA of the knee with symptoms for at least 6 months and pain
on the majority of days in the last 30 days. Symptoms must include knee joint pain.
2. Male or female adults age >40 years with a body mass index <35
3. Radiographic evidence of at least one osteophyte in either knee on posteroanterior
(PA) and lateral standing, flexed x-ray.
4. A Kellegren-Lawrence score of 2-3, or KL score of 1 accompanied by a clinically
apparent effusion in the index knee.
5. A WOMAC pain score of >8 on the index knee at screening visit.
1. A requirement for treatment with high potency opioids for pain relief.
2. Unwilling to abstain from NSAIDs and/or other analgesic medications except
acetaminophen (i.e., COX-2 inhibitors, tramadol) for 48 hours and acetaminophen for 24
hours prior to pain assessments during the study. Subjects taking low dose aspirin for
cardiovascular health may remain on their stable dose throughout the study.
3. On an unstable dose of NSAIDs or analgesics for at least 1 months prior to screening
4. Using a handicap assistance device (i.e., cane, walker) >50% of the time.
5. Undergoing new physical therapy or participating in a weight loss or exercise program
that has not been stable for at least 3 months prior to screening visit 1 and will not
remain stable during their participation in the study.
6. Had a previous history of arthroscopic or open surgery to the index knee in the past 6
months or planned surgery during study follow up.
7. Had joint replacement surgery in the index knee.
8. Received corticosteroid, short acting hyaluronic acid, or other intraarticular
injections of the index knee within 3 months of screening visit 1 and/or not willing
to abstain from treatments for the duration of the study
9. A history in the past 5-10 years of reactive arthritis, rheumatoid arthritis,
psoriatic arthritis, ankylosing spondylitis, arthritis associated with inflammatory
bowel disease, sarcoidosis, amyloidosis or fibromyalgia.
10. Clinical signs and symptoms of active knee infection or radiographic evidence of
crystal disease other than chondrocalcinosis (i.e. gout).
11. A history of abnormal laboratory results >2.5 x ULN indicative of any significant
medical disease, which in the opinion of the investigator, would preclude the subjects
participation in the study
12. Any of the following abnormal laboratory results during screening:
- ALT and/or AST >2.5x ULN
- Hemoglobin <9 g/dL
- WBC <3500 cells/mm3
- Lymphocyte count <1000 cells/mm3
- Serum creatinine >1.5 x ULN or calculated Glomerular filtration rate less than
- Creatine phosphokinase level > 2x ULN
13. A history of malignancy in the past ten years (<10 years), with the exception of
resected basal cell carcinoma, squamous cell carcinoma of the skin, or resected
cervical atypia or carcinoma in situ.
14. Significant hip pain, ipsilateral to the index knee that may interfere with
assessments of index knee pain
15. A known or clinically suspected infection with human immunodeficiency virus (HIV), or
hepatitis C or B viruses
16. Participated within 3 months or will participate concurrently in another
investigational drug or vaccine study
17. A history of drug or alcohol dependence or abuse in the past 3 years
18. A female with reproductive capability who is unwilling to use birth control for the
duration of the study and/or intends to conceive within 12 months of dosing.
19. Ongoing use of hydroxychloroquine, or any anti-malarial, or prior history of use
within past 3 months or any prior history of history of allergy, hypersensitivity or
toxicity to antimalarial use.
20. Ongoing use of a statin (HMG Co A reductase inhibitor), or use within past 3 months or
any prior history of history of allergy, hypersensitivity, or toxicity to statin use.
21. Use of fibric acid derivative in past 3 months.
22. Other serious, non-malignant, significant, acute or chronic medical or psychiatric
illness that, in the judgment of the investigator, could compromise subject safety,
limit the subject's ability to complete the study, and/or compromise the objectives of
Ages Eligible for Study
40 Years - N/A
Genders Eligible for Study